Loading company…
Riskpilot
← Back to search
Sign in
Get full access
BP PHARMA CONSULT ApS
APS
In liquidation
CVR 34880840
Mosestedet 53
Engineering activities and related technical consultancy · NACE 7112
Est. 2012
2 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2014
DKK 1,4M
0% vs 2013
EBITDA margin
61.9%
0% vs 2013
Equity ratio
58.0%
Financial strength
Net profit 2014
DKK 640K
0% vs 2013
EBITDA — year on year
DKK millions
1M
1M
1M
0M
0M
1M
2013
1M
0%
2014
Key figures
Annual report 2014
Revenue
DKK 1,4M
+0%
EBITDA
DKK 881K
+0%
Net profit
DKK 640K
+0%
Total assets
DKK 1,2M
+0%
Equity
DKK 720K
+0%
Employees
2
—
Company information
Legal name
BP PHARMA CONSULT ApS
CVR number
34880840
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
5. december 2012
Share capital
DKK 80.000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2014-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Contact
Address
Mosestedet 53
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Engineering activities and related technical consultancy
Companies in Furesø
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
1M
2013
1M
2014
EBITDA
DKK millions
0M
0M
1M
1M
1M
1M
2013
1M
2014
Income statement
DKK thousands
Item
2013
2014
Revenue
1.423
1.423
Staff expenses
-542
-542
EBITDA
881
881
Depreciation & amort.
-14
14
EBIT
867
867
Net financials
-10
-10
Profit before tax
857
857
Tax
217
217
Net profit
640
640
Balance sheet
DKK thousands
Item
2013
2014
Total assets
1.242
1.242
Equity
720
720
Long-term debt
0
229
Short-term debt
521
521
Total debt
521
521
Financial ratios
5-year trend
EBITDA margin
61.9%
This company
15.8%
Market median
+292% vs market
2013
2014
Equity ratio
58.0%
This company
38.2%
Market median
+52% vs market
2013
2014
Return on equity
88.9%
This company
18.4%
Market median
+383% vs market
2013
2014
Net profit margin
45.0%
This company
8.1%
Market median
+456% vs market
2013
2014
Asset turnover
1.15×
This company
1.12×
Market median
+3% vs market
2013
2014
Debt / equity
0.72×
This company
0.62×
Market median
+16% vs market
2013
2014
Annual reports & filings
Annual report 2014
Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
View
PDF
Annual report 2013
Filed via CVR / Virk · Period 2012-12-05 – 2013-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Former (2)
CB
Claus Bærentzen
Management
Management
2012 – 2015
UM
Ulrik Møller
Unofficial title
Unofficial title
2015 – 2016
Board of directors
Non-executive oversight
Name
Role
Member since
Former (3)
BS
Birgit Søndergaard Pedersen
Board of Directors
2012 – 2015
SS
Signe Sommer Bærentzen
Board of Directors
2012 – 2015
EB
Erik Bærentzen
Chairman
2012 – 2015
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
BP PHARMA HOLDING ApS
Company
100%
100%
2013
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of BP PHARMA CONSULT ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Claus Bærentzen
Management
0 companies
Ulrik Møller
Unofficial title
0 companies
Birgit Søndergaard Pedersen
Board of Directors
0 companies
Signe Sommer Bærentzen
Board of Directors
0 companies
Erik Bærentzen
Chairman
0 companies